The current financial score of Zymeworks Inc is 6.59. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 4.59M, representing a year-over-year decrease of 90.58%, while its net profit experienced a year-over-year decrease of 2042.99%.
The current valuation score of Zymeworks Inc is 8.51. Its current P/E ratio is -20.13, which is -126.15% below the recent high of 5.26 and -67.72% above the recent low of -33.76.
The current earnings forecast score of Zymeworks Inc is 8.67. The average price target is 41.92, with a high of 60.00 and a low of 32.00.
The current price momentum score of Zymeworks Inc is 3.96. Currently, the stock price is trading between the resistance level at 30.62 and the support level at 25.09, making it suitable for range-bound swing trading.
The current institutional shareholding score of Zymeworks Inc is 10.00. The latest institutional shareholding proportion is 105.96%, representing a quarter-over-quarter increase of 3.89%. The largest institutional shareholder is Ken Fisher, holding a total of 70.78K shares, representing 0.00% of shares outstanding, with 10.11% decrease in holdings.
The current risk assessment score of Zymeworks Inc is 6.78. The company's beta value is 1.16. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.